Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Quiescence

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44364   clinical trials with a EudraCT protocol, of which   7388   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    9 result(s) found for: Quiescence. Displaying page 1 of 1.
    EudraCT Number: 2006-004876-10 Sponsor Protocol Number: ASF-EVER.1 Start Date*: 2007-08-06
    Sponsor Name:Department of Ophthalmology at St. Franziskus Hospital
    Full Title: single center study on safety and efficacy of everolimus in patients with endogenous intermediate and posterior uveitis
    Medical condition: Uveitis, specially endogenous interemdiate and posterior uveitis
    Disease: Version SOC Term Classification Code Term Level
    8.1 10046851 Uveitis LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2009-014834-22 Sponsor Protocol Number: CAIN457C2302 Start Date*: 2010-07-06
    Sponsor Name:Novartis Farmacéutica, S.A.
    Full Title: Estudio Fase III, multicéntrico, aleatorizado con doble enmascaramiento, controlado con placebo, de determinación de dosis y 28 semanas de duración, para evaluar AIN457 frente a placebo en la induc...
    Medical condition: determinación de dosis y 28 semanas de duración, para evaluar AIN457 frente a placebo en la inducción y mantenimiento de la supresión de la uveítis en adultos con uveítis activa no infecciosa inter...
    Disease: Version SOC Term Classification Code Term Level
    11 10022557 Uveítis intermedia PT
    11 10036370 Uveítis posterior LLT
    11 10033687 Panuveítis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Prematurely Ended) HU (Prematurely Ended) GB (Completed) DE (Prematurely Ended) FR (Prematurely Ended) IT (Prematurely Ended) GR (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2011-005573-23 Sponsor Protocol Number: 2914-015 Start Date*: 2012-02-20
    Sponsor Name:Laboratoire HRA Pharma
    Full Title: A prospective, randomized, double-blind parallel-arm, placebo-controlled study to assess the effects on ovarian activity of a combined oral contraceptive pill when preceded by the intake of ellaOne...
    Medical condition: Contraception
    Disease:
    Population Age: Adults Gender: Female
    Trial protocol: SE (Completed) NL (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2017-002283-41 Sponsor Protocol Number: 151032-002 Start Date*: 2017-09-11
    Sponsor Name:HRA Pharma
    Full Title: A prospective, randomized, parallel-group study to assess the effects on ovarian activity of ellaOne (ulipristal acetate 30 mg single dose) taken after three consecutive days of missed combined ora...
    Medical condition: Emergency contraception
    Disease:
    Population Age: Adults Gender: Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2021-006498-49 Sponsor Protocol Number: 21103 Start Date*: 2022-08-18
    Sponsor Name:ACELYRIN, Inc.
    Full Title: A Phase 2b Pivotal Study to Evaluate the Efficacy and Safety of Izokibep in Subjects with Non-infectious, Intermediate-, Posterior- or Pan-uveitis
    Medical condition: Non-infectious, Intermediate-, Posterior- or Pan-uveitis
    Disease: Version SOC Term Classification Code Term Level
    22.1 100000004853 10022557 Intermediate uveitis LLT
    20.1 100000004862 10036370 Posterior uveitis LLT
    20.0 100000004853 10033687 Panuveitis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned) DE (Trial now transitioned) CZ (Trial now transitioned) ES (Ongoing) IT (Trial now transitioned) AT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2006-005008-15 Sponsor Protocol Number: Okhn1001 Start Date*: 2006-11-08
    Sponsor Name:Moorfields Eye Hospital NHS Foundation Trust
    Full Title: Exploratory study of intravitreal clindamycin and dexamethasone in the treatment of acute toxoplasma chorioretinitis associated vitritis
    Medical condition: Vitritis secondary to acute toxoplasma chorioretinitis
    Disease: Version SOC Term Classification Code Term Level
    8.1 10008770 Chorioretinitis due to toxoplasmosis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2009-015509-38 Sponsor Protocol Number: CAIN457C2302E1 Start Date*: 2010-10-19
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A 34-week extension to a 28-week multicenter, randomized, double-masked, placebo controlled, dose-ranging phase III study to assess AIN457 versus placebo in inducing and maintaining uveitis suppres...
    Medical condition: Non-infectious, intermediate uveitis, posterior uveitis or panuveitis
    Disease: Version SOC Term Classification Code Term Level
    12.1 10046851 Uveitis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) GB (Completed) HU (Prematurely Ended) GR (Prematurely Ended) ES (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2006-006544-66 Sponsor Protocol Number: LX211-02-UV Start Date*: 2007-04-13
    Sponsor Name:Lux Biosciences GmbH
    Full Title: A Double-Masked, Placebo-Controlled, Parallel-Group, Multi-Centre, Dose-Ranging Study with an Optional Extension to Assess the Efficacy and Safety of LX211 as Therapy in Subjects with Clinically Qu...
    Medical condition: Subjects with clinically quiescent sight-threatening, non-infectious intermediate-, anterior and intermediate-, posterior- or pan-uveitis requiring systemic immune suppression.
    Disease: Version SOC Term Classification Code Term Level
    8.1 10046851 Uveitis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) FR (Completed) GB (Completed) AT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2009-015508-24 Sponsor Protocol Number: CAIN457C2301E1 Start Date*: 2010-02-15
    Sponsor Name:Novartis Farmacéutica, S.A.
    Full Title: Extensión de 38 semanas del Estudio Fase III, multicéntrico, aleatorizado con doble enmascaramiento, controlado con placebo, de determinación de dosis y 24 semanas de duración, con el objetivo de e...
    Medical condition: Terapia adyuvante para el tratamiento de uveitis intermedia, uveitis posterior o panuveitis que precisen inmunosupresión sistémica
    Disease: Version SOC Term Classification Code Term Level
    12.0 10022941 Iridocyclitis LLT
    9 10022557 Intermediate uveitis LLT
    9 10033687 Panuveitis LLT
    9 10036370 Posterior uveitis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Prematurely Ended) GB (Prematurely Ended) DE (Prematurely Ended) IT (Prematurely Ended)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Thu Nov 06 20:22:10 CET 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA